Showing results (101-110 of 522) with videos related to
Sort By:
Pageof 53
Nature Reviews. Clinical Oncology|March 15, 2025
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trialsSophie M Ernst, Mihaela Aldea, Jan H von der Thüsen, et al.Clinical Lung Cancer|November 23, 2021
PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung TrialJérôme Doyen, Benjamin Besse, Matthieu Texier, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2019
Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?Diego Enrico, Angelo Paci, Nathalie Chaput, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2019
Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal MetastasesRonan Flippot, Pamela Biondani, Edouard Auclin, et al.Cancers|July 9, 2022
Radon and Lung Cancer: Current Trends and Future PerspectivesMariona Riudavets, Marta Garcia de Herreros, Benjamin Besse, et al.Cancer Treatment Reviews|September 11, 2017
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?Roberto Ferrara, Laura Mezquita, Edouard Auclin, et al.International Journal of Clinical Pharmacy|May 11, 2018
Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapyFlorian Slimano, Florence Netzer, Isabelle Borget, et al.Translational Lung Cancer Research|August 25, 2021
How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative reviewJordi Remon, Jessica Menis, Antonin Levy, et al.European Radiology|April 24, 2020
Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinomaAlison Dormieux, Laura Mezquita, Paul Henry Cournede, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP RegistryArianna Marinello, Julia K Rotow, Meghanne Lomibao, et al.Pageof 53